Abstract 14P
Background
C-Myc promoter binding protein (MBP-1) is a product of alternatively translated mRNA encoding alpha-enolase (ENO-1). In contrast to ENO-1, MBP-1 possesses no enzymatic activity but instead is able to bind P2 region of the c-Myc promoter leading to the modulation of its expression. Ectopic overexpression of MBP-1 was shown to reduce cell proliferation and tumorigenicity of numerous tumor cell lines, hence constituting an attractive target for cancer therapy.
Methods
We created lentiviral particles encoding HA-tagged, human MBP-1 protein, its C-terminal deletion mutant (MBP-1ΔC), or control, empty pRLL puro vector. With these tools, we created six stable transfectants derived from A375 and WM9 human melanoma cell lines. Detection of HA-tag by Western blot and immunofluorescence confirmed the overexpression of transfected proteins. We then used qPCR to estimate the effects of MBP-1 overexpression on the c-Myc transcription, Click-it Edu proliferation assay to assess the rate of cell proliferation, lactate detection assay in hypoxia and normoxia to measure the glycolytic rate and in vitro wound-healing assay to evaluate the migration ability of transduced cells.
Results
In our study, we found that overexpressed MBP-1 and MBP-1ΔC predominantly localized in the cytoplasm and only minimally decreased c-Myc mRNA expression, secondly, the proliferation rate of MBP-1- transduced cells increased in comparison to empty vector controls, and thirdly, the rate of glucose metabolism in normoxia and hypoxia increased in MBP-1 and MBP-1ΔC transduced cells. When assessing cell migration, we also found that overexpression of MBP-1 but not MBP-1ΔC led to a substantial decrease in the cell migration capacity of WM9 but not A375.
Conclusions
Our data underline potential pitfalls to avoid when overexpressing MBP-1 by means of lentiviral vectors. We provide evidence suggesting that lentiviral transduction of melanoma cell lines per se strongly affects cell proliferation and glucose metabolism. On the other hand, our research depicted an unexpected tumor-promoting activity of MBP-1 that can be largely dissociated from its nuclear localization and enzymatic activity.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Wroclaw Medical University, Wroclaw University of Environmental and Life Sciences.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
74P - Tumor agnostic comparison of immunohistochemistry and next-generation sequencing in detecting ALK fusions and assessment of ALK tyrosine kinase inhibitor efficacy
Presenter: Monica Chen
Session: Cocktail & Poster Display session
Resources:
Abstract
75P - Target identification by TIME phenotypes
Presenter: Robert Seitz
Session: Cocktail & Poster Display session
Resources:
Abstract
76P - Prediction of response to palliative chemotherapy by circulating tumor DNA (ctDNA) kinetics in metastatic pancreatic cancer
Presenter: Patrick Kirchweger
Session: Cocktail & Poster Display session
Resources:
Abstract
77P - Impact of germline HLA genotypes on clinical outcomes in patients (pts) with solid tumors treated with immunotherapy
Presenter: Katerin Rojas Laimito
Session: Cocktail & Poster Display session
Resources:
Abstract
78P - High resolution in situ analysis reveals phenotypic and functional diversification within single pancreatic tumour ducts
Presenter: Ellis Michiels
Session: Cocktail & Poster Display session
Resources:
Abstract
81P - Implementing genomic profiling as standard-of-care for glioblastoma patients
Presenter: Vincent Fougner
Session: Cocktail & Poster Display session
Resources:
Abstract
82P - Cyclic fasting-mimicking diet as a strategy to improve the efficacy of standard antitumor therapies in cancer patients
Presenter: Filippo Guglielmo Maria De Braud
Session: Cocktail & Poster Display session
Resources:
Abstract
83P - Evaluation of response-predictive biomarkers for lisavanbulin: A phase II study in patients with recurrent glioblastoma
Presenter: Juanita Lopez
Session: Cocktail & Poster Display session
Resources:
Abstract
84P - Racial disparities in phase I lung cancer clinical trials
Presenter: Rohit Singh
Session: Cocktail & Poster Display session
Resources:
Abstract
85P - Stereotactic radiotherapy improves disease control in oligoprogressive patients included in early clinical trials
Presenter: Antoine Mavrikios
Session: Cocktail & Poster Display session
Resources:
Abstract